CAMBRIDGE, Mass, April 15, 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, today announced its participation at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, taking place virtually April 29-30. Daniel Getts, Ph.D., Chief Executive Officer of Myeloid, will participate in a fireside chat […]
Presented data support the ongoing clinical assessment of MT-302, the world’s first in vivo mRNA CAR drug development candidate Additional updates highlight Myeloid’s pioneering work, including a set of novel mRNA CAR constructs for in vivo programming of additional immune cell subsets, including NK and T cells CAMBRIDGE, Mass, April 4, 2024 – Myeloid Therapeutics, […]
CAMBRIDGE, Mass, March 5, 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage immunology company, today announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, at the San Diego Convention Center. Details follow: Title: In vivo programming […]
CAMBRIDGE, Mass, October 2, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the following investor conferences: Chardan’s 7th Annual Genetic Medicines Conference, taking place October 2-3, 2023, in NY Oppenheimer’s Private Company Symposium, taking place October 11, 2023, in NY 3rd Annual Needham Private Biotech […]
CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the following investor conferences: Citi’s 18th Annual BioPharma Conference, taking place September 5-7, 2023, in Boston, MA Management will participate in a fireside chat on September 6, 2023, at 11:20 am ET. […]
CAMBRIDGE, Mass, May 22, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the SVB Securities Biopharma Company Connect event, taking place virtually May 24th- 25th, 2023. Myeloid management will participate in virtual one-on-one meetings with investors during the event. About Myeloid Therapeutics Myeloid Therapeutics is […]